Background Activating BRAF V600E (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patients with advanced non-small-cell lung cancer (NSCLC) positive for the BRAF V600E mutation.
Introduction
Non-small-cell lung cancer (NSCLC) accounts for around 85% of all lung cancers and remains a major cause of cancer-related deaths worldwide. 1 In the past few decades, important advances have been made in defi ning the molecular pathogenesis of lung cancers-particularly detection of crucial oncogenic drivers-that have accelerated development of targeted agents. Constitutively activating mutations in the BRAF gene, which were fi rst described in lung cancer, 2, 3 drive growth and survival of the cancer cells that harbour them, and are extremely sensitive to selective BRAF-inhibitor therapy across multiple tumour types. 4 In a transgenic murine lung cancer model, BRAF V600E (Val600Glu) mutations behaved as oncogenic drivers. 5 BRAF mutations are present in about 2-4% of lung adenocarcinomas, and roughly 50% of those are BRAF V600E mutations. 2, [6] [7] [8] Patients with BRAF V600E mutations have shorter overall survival and smaller proportions of patients respond to platinum-based chemotherapy than patients with wild-type BRAF. 9, 10 Treatment options for patients with BRAF V600E mutations are limited and outlook is poor; therefore, novel therapeutic strategies are needed. Of note, BRAF mutations and other oncogenic drivers, including EGFR and RAS mutations and ALK rearrangements, are typically mutually exclusive. This fi nding is consistent with the notion that the BRAF mutation defi nes a unique molecular subset of patients with NSCLC who might benefi t from treatment with BRAF inhibitors.
Much of the clinical experience with BRAF inhibitors in BRAF V600E -positive NSCLC has been limited to isolated cases and a retrospective case series. [11] [12] [13] [14] The activity of the BRAF V600E inhibitor vemurafenib was assessed in patients with various solid tumours and haematological malignancies in a basket study that included 19 patients with BRAF V600E -positive NSCLC, of whom 42% achieved an overall response. 15 Dabrafenib is a potent adenosinetriphosphate-competitive inhibitor of BRAF kinase selective for the BRAF V600E mutation in kinase panel screening, cell lines, and xenografts. 16 This drug is approved in the USA and Europe for the treatment of unresectable or metastatic BRAF V600E -positive melanoma. We aimed to investigate the clinical activity and safety of dabrafenib for the treatment of patients with advanced or metastatic BRAF V600E -positive NSCLC.
Methods

Study design and participants
This study was part of a continuing phase 2, multicentre, non-randomised, open-label study and recruited patients from 34 centres in ten countries within North America, Europe, and Asia (appendix pp [3] [4] . Enrolment for the cohort reported here has been completed. In two other cohorts, clinical activity and safety of the combination of dabrafenib plus trametinib is being assessed in patients with previously treated advanced or metastatic BRAF V600E -positive NSCLC and in treatment-naive patients. The three cohorts were enrolled sequentially. The results for the other two cohorts will be reported elsewhere. Eligible patients were aged 18 years or older and had histologically confi rmed stage IV BRAF V600E -mutated NSCLC that had progressed after at least one systemic treatment for metastatic disease. Patients who had received no previous systemic anticancer therapy for metastatic disease could be enrolled after a protocol amendment in April, 2013, an interim analysis showed that overall response, duration of response, and the safety profi le in patients receiving second-line or later therapy supported the use of dabrafenib before chemotherapy in fi rst-line patients. However, after discussions with regulatory agencies, enrolment of fi rst-line patients was delayed until after that of the cohort assigned dabrafenib plus trametinib, because an increased proportion of patients achieving a response was expected with combination therapy. BRAF V600E mutation status was established by local test results in laboratories certifi ed by Clinical Laboratory Improvement Amendments (or equivalent), and disease was classifi ed according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Other inclusion criteria were an Eastern Cooperative Oncology Group performance status of 2 or lower, a tumour sample adequate for central confi rmation of BRAF V600E mutation (ten to 15 unstained slides with 50% or more tumour content), and an anticipated life expectancy longer than 3 months. All enrolled patients were asked to provide archival tumour tissue or, if no sample was available, to undergo a biopsy before the fi rst treatment dose. Patients with inadequate tumour samples after enrolment were allowed to stay in the study, and we amended the protocol in April, 2013, to allow enrolment of additional patients to ensure the number with centrally confi rmed BRAF 
Research in context
Evidence before this study For most patients with advanced non-small-cell lung cancer (NSCLC), conventional cytotoxic chemotherapy, with or without bevacizumab, is the standard treatment, but it off ers only a small survival benefi t. Oncogenic drivers of NSCLC have been identifi ed, which has led to the development of targeted agents, particularly small-molecule tyrosine-kinase inhibitors targeting EGFR and ALK. Oncogenic mutations of BRAF, a serine-threonine protein kinase in the RAF/MEK/ERK pathway, are rare in NSCLC (around 2% of tumours). Importantly, most cancer cells harbouring BRAF V600E (Val600Glu) mutations are dependent on the activity of this oncogene for growth and survival, and are exquisitely sensitive to selective BRAF and MEK inhibitors. In melanoma, two selective BRAF inhibitors, vemurafenib and dabrafenib, have gained regulatory approval in the USA and Europe for the treatment of patients with unresectable or metastatic BRAF V600 -positive disease. Importantly, BRAF V600E mutations are thought to correlate with more aggressive tumours, which implicates the BRAF V600E mutation as an oncogenic driver and provides a robust rationale for the use of dabrafenib in genotype-selected patients.
We searched PubMed for studies of BRAF inhibitors in the treatment of BRAF V600 -positive NSCLC, without date limitations. We used the search terms "dabrafenib", "vemurafenib", "GSK2118436", and "PLX4032", all with "non-small cell lung cancer OR NSCLC". We identifi ed a prospective basket study of vemurafenib used to treat non-melanoma cancers, including 19 patients with BRAF V600 -positive NSCLC. Other reports were case studies and a retrospective case series that involved 35 patients in total. We found no studies of targeted BRAF-inhibitor therapy exclusively in patients with BRAF V600E -positive NSCLC.
Added value of this study
We found that dabrafenib had substantial antitumour activity (proportion with overall response 33%) in patients with BRAF
V600E
-positive advanced NSCLC. The clinical responses were durable in a substantial proportion of patients in our study and the safety profi le was tolerable.
Implications of all the available evidence
In this prospective trial assessing targeted BRAF-inhibitor treatment exclusively in patients with BRAF
V600E
-positive NSCLC, our results highlight the importance of screening for specifi c genetic alterations before treatment in patients with advanced NSCLC. The clinical benefi t of dabrafenib seems to be better than that associated with unselected treatments in NSCLC, including docetaxel and EGFR tyrosine-kinase inhibitors, although cross-trial comparisons must be done with caution. Because BRAF V600 mutations are rare in NSCLC, which limits the possibility of doing randomised trials, and because benefi ts derived from second-line chemotherapy are small, our results could potentially change management strategies in this cancer.
[≥0⋅8 mL/s per m²]), and coagulation (prothrombin time or international normalised ratio and partial thromboplastin time up to 1⋅5 × ULN). Patients with EGFR mutations or ALK rearrangements were eligible if they had previously received, respectively, EGFR or ALK inhibitors.
Patients were excluded if they had previously been treated with a BRAF or MEK inhibitor or had symptomatic or unstable brain metastases, had anticancer treatment (including chemotherapy, radiation therapy, immunotherapy, biological therapy, or major surgery) within 14 days of starting dabrafenib or treatment with an investigational anticancer drug within 14 days or fi ve half-lives of starting dabrafenib, known infection with hepatitis B or C virus, history or signs of cardiovascular risk (left ventricular ejection fraction at or above the lower limit of normal on echocardiography), and pregnancy. Patients with asymptomatic, untreated brain metastases smaller than 1 cm could be enrolled.
This study was done in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by the institutional review board at each participating institution. All patients gave written informed consent.
Procedures
Patients were treated with dabrafenib 150 mg orally twice daily until disease progression or unacceptable adverse events, withdrawal of consent, or death. Study treatment could also be discontinued for any of the following reasons: protocol deviation, request by the patient, decision by the investigator, loss to follow-up, or study closure or termination. Dose interruptions and modifi cations were used to manage intolerable grade 2 or worse adverse events. Doses were sequentially reduced to 100, 75, or 50 mg twice daily, dependent on event severity, and could be re-escalated when the adverse event had resolved. Treatment was discontinued in patients who could not tolerate 50 mg twice daily. Patients with progressive disease were permitted to continue dabrafenib if they had a confi rmed response (complete response or partial response) or stable disease lasting at least 12 weeks during treatment and the investigator believed that the patient was clinically benefi ting from therapy.
Baseline disease assessment included contrast-enhanced CT of the chest and abdomen and clinical assessment for palpable lesions. In patients with known brain metastases, contrast-enhanced brain MRI or head CT was done at baseline and repeated during each disease assessment. Baseline medical history, physical examination, laboratory tests, collection of demographic data, and cardiac and radiological tumour assessments were done within 28 days before the fi rst dose of dabrafenib.
Safety was assessed at least once every 3 weeks. Adverse events, haematology and clinical chemistry laboratory values, and vital signs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Cardiac assessments with echocardiography and electro cardiography were done at baseline, week 6, week 15, and every 9 weeks thereafter. Radiological disease assessments with CT based on RECIST 1.1 were done every 6 weeks until week 36, then every 12 weeks, with any responses confi rmed by repeat assessment 28 days or later after the initial response. Scans used to assess the primary endpoint and all time-to-event endpoints except for overall survival were also reviewed by an independent review committee as well. All patients who discontinued study medication were followed up, with subsequent treatments and survival being recorded every 12 weeks, until death or study completion. Safety data were analysed three times per year by an independent data monitoring committee.
Outcomes
The primary endpoint was investigator-assessed overall response, which was defi ned as the proportion of patients
Patients receiving dabrafenib as second-line or later treatment (n=78)
Age (years) 66 ( with a confi rmed complete response or partial response. Secondary endpoints were progression-free survival (defi ned as the time between the fi rst dose of dabrafenib and the earliest documentation of disease progression or death from any cause), duration of response (time from fi rst documented evidence of complete response or partial response to the earlier of fi rst documented disease progression or death from any cause), disease control (defi ned as the proportion of patients with an overall response or stable disease) for longer than 12 weeks, overall survival (defi ned as the time from fi rst dose to death from any cause), pharmacokinetic assessment, and safety and tolerability of dabrafenib.
Statistical analysis
On the basis of previous reports in patients with advanced unselected NSCLC receiving second-line or third-line single-agent chemotherapy or erlotinib, we anticipated that an overall response would be achieved in 7-10% of patients. 17, 18 The null hypothesis was that the overall response would not be clinically meaningful (10% or less) and the alternative hypothesis was that it would be clinically meaningful (30% or greater) and, therefore, the drug would warrant further development. To allow early termination of the trial due to lack of activity, we assessed overall response at an interim timepoint, in line with a two-stage Green-Dahlberg design for phase 2 cancer trials, 19 with planned enrolment of 20 patients in each stage (appendix p 5). This design corresponded to a type I error of 0·038 and power of 92·6%. To further refi ne the 95% CI for overall response, the number of patients was increased by planned enrolment of 20 additional patients who had received at least one previous treatment (secondline patients) and treatment-naive patients could be enrolled.
The primary analyses of clinical activity were done in patients who received at least one dose of dabrafenib as a second-line or later treatment (previously treated patients). We estimated median duration of response, progressionfree survival, and overall survival with the Kaplan-Meier method, and used the Brookmeyer-Crowley method to calculate corresponding two-sided 95% CIs. 20 For overall response we used the Clopper-Pearson method to calculate 95% CIs. 21 Sensitivity analyses for these endpoints were done with data from the independent review committee and the same statistical methods. Patients who had not received previous systemic therapy for metastatic disease were included in an exploratory analysis of activity and progression-free survival. Exploratory analyses used the same methods as those used for the primary and secondary endpoints. Post-hoc subgroup analyses of clinical activity used the same methods as those used for the primary analysis. All patients who received at least one dose of study drug were included in the safety analysis.
A protocol-mandated analysis of clinical activity was done in April 30, 2014 , when the investigators and sponsor believed that enrolment was suffi cient to include 60 previously treated patients with measurable disease (appendix pp 5, 8, 10) . In this analysis the data on duration of response were immature and, therefore, here we report data from an updated analysis that was done on Nov 21, 2014 . Because this updated analysis was intended only to provide updated clinical activity, safety analyses reported here are from the protocol-mandated 
Role of the funding source
The funder was involved in the design of the study, data collection, data analysis, data interpretation, and writing of the report. Editorial support that did not involve writing was provided by ArticulateScience and funded by the sponsor. LP, CN, BMa, AD'A, BMo, and CMC had access to all the data in the study and the corresponding author had fi nal responsibility for the decision to submit for publication.
Results
Between Aug 3, 2011, and Feb 25, 2014, 84 patients were enrolled, 78 of whom had received at least one previous chemotherapy regimen (table 1) and six patients who were receiving dabrafenib as fi rst-line treatment (fi gure 1). Central confi rmation of BRAF V600E mutation status has not yet been completed.
Baseline characteristics of the 78 patients receiving dabrafenib as a second-line or later treatment (previously treated patients) are shown in table 1. Baseline characteristics for the six patients who had received no previous systemic anticancer therapy for metastatic disease are presented in the appendix (p 5). As of Nov 21, 2014, nine (12%) of 78 previously treated patients were still being treated with dabrafenib, 69 (88%) had discontinued therapy, and 46 (59%) had died.
The median duration of exposure to dabrafenib for all patients was 4·6 months (IQR 1·8-11·1; appendix p 11). With a median follow-up of 10•7 months (IQR 4•5-16•2), investigator-confi rmed overall response was reported in 26 (33%; 95% CI 23-45) of 78 previously treated patients (all partial responses). 19 (73%) initial objective responses were recorded at the fi rst disease assessment 6 weeks from baseline, three at week 12, two at week 18, one at week 24, and one at week 36. Among the 78 previously treated patients, the independent review committee judged that 64 (82%) had measurable disease at baseline. As a sensitivity analysis, the proportion of patients with an overall response according to independent review was 21 (33%; 95% CI 22-46) of 64 patients: one patient had a complete response and 20 had a partial response. Best confi rmed response based on investigator assessment is shown in fi gure 2 and disease control is shown in table 2. Investigator-assessed and independently assessed duration of response is shown in table 2 and fi gure 3. The overall response results at the time of the protocolmandated analysis were similar to those of the updated analysis (appendix pp 5, 8, 10) . 59 (76%) of 78 patients had disease progression or had died at the time of the updated analyses. Investigatorassessed survival was similar to independently assessed progression-free survival (table 2, appendix pp 12-13). 46 (59%) of 78 patients had died by the time of the analysis and median overall survival was 12·7 months (95% CI 7·3-16·9; appendix p 14).
Four of the six patients receiving fi rst-line treatment with dabrafenib (previously untreated patients) were deemed by investigators to have achieved a partial response. Progression-free survival in these patients was 4·5, 8·6, 11·0, and 16·6 months, and the corresponding durations of response were 3·2, 7·2, 9·6, and 12·5 months. The two patients without a response had progression-free survival of 4·0 and 8·1 months.
Patients received a median dose of dabrafenib of 296·2 mg per day (IQR 269·1-300·0), which represents 98·7% of the intended dose of 300 mg per day. As of April 30, 2014, 83 (99%) of 84 patients had had at least one adverse event, with 45 (54%) of 84 patients having had adverse events of grade 2 or worse (table 3; appendix p 9). The most frequent grade 3 or worse adverse events were the development of cutaneous squamous-cell carcinoma Data are n (%), n (%, 95% CI), or median (95% CI). SD=stable disease. *SD for ≥12 weeks from baseline. †Confi rmed response or SD for ≥12 weeks after start of treatment. ‡Four because of no assessment after baseline (three due to adverse events and one decision to transfer to palliative care) and six because of discontinuation before 12 weeks without disease progression (all SD <12 weeks). and none of these patients needed a dose modifi cation or interruption. No squamous-cell carcin omas were seen in other organs. In 77 (92%) of 84 patients, adverse events were judged to be related to the study treatment. Five (6%) patients had adverse events that led to dabrafenib discontinuation (blistering, deterioration of general health, intracranial haemorrhage, malaise, and palmarplantar erythrodysaesthesia syndrome [all n=1]). 36 (43%) patients had a treatment-related dose interruption; the most common adverse events leading to dose interruption were pyrexia in nine (11%) patients, chills in fi ve (6%), and vomiting in four (5%). 15 (18%) patients had a treatmentrelated dose reduction; the most common adverse events leading to dose reductions were palmar-plantar erythrodysaesthesia in three (4%) patients and pyrexia in three (4%). Serious adverse events were reported in 35 (42%) of 84 patients; the most frequent serious adverse events were pyrexia in fi ve (6%) of 84 patients, decreased ejection fraction in two (2%), and pneumonia in two (2%; appendix p 9). One patient, who was taking a factor Xa inhibitor, died during the study from an intracranial haemorrhage that was reported within 2 weeks of starting dabrafenib and was judged to be related to the study treatment. One patient with asymptomatic brain metastasis at baseline had no visible brain lesion at the 6 week and 12 week tumour assessments, but the patient left the study because of non-adherence. Four patients developed new brain metastases during the study.
A post-hoc analysis of response based on number of previous treatments showed an overall response in 15 (38%) and disease control in 26 (65%) of 40 patients who had previously received one line of therapy, compared with 11 (29%) and 19 (50%) of 38 patients who had received two or more previous lines of therapy (appendix p 6). In a post-hoc analysis of response based on smoking history, 15 (52%) of 29 patients with no smoking history had an overall response, compared with six (24%) of 25 patients with a history of less than 30 pack-years and fi ve (21%) of 24 patients with a history of 30 pack-years or more (appendix p 7).
Pharmacokinetic assessment is not complete and no analysis has been done. These data will be reported elsewhere.
Discussion
This phase 2 study showed antitumour activity of dabrafenib in patients with BRAF V600E -positive NSCLC. The confi rmed overall response was 33% and disease control was achieved in 58% of 78 patients who had previously received treatment for metastatic disease. Additionally, response was rapid, with 73% of patients having a partial response noted at the fi rst assessment 6 weeks from baseline. Results from an independent review of clinical activity data were consistent with those from the investigator assessments.
Targeted treatment options for patients with advanced NSCLC have so far been limited except for patients with cancers that harbour activating mutations in the EGFR gene or ALK rearrangements. 22, 23 The antitumour activity of BRAF inhibitors in patients with metastatic BRAF V600E -positive lung cancers has been primarily reported in isolated clinical cases, one retrospective case series of 35 patients, and a phase 2 basket trial of 19 patients. [11] [12] [13] [14] [15] The phase 2 basket trial assessed the BRAF inhibitor vemurafenib in patients with NSCLC and unspecifi ed BRAF V600 mutations, and reported an overall response of 42% (95% CI 20-67) and median progressionfree survival of 7·3 months (95% CI 3⋅5-10⋅8). 15 Crosstrial comparisons should be interpreted with caution, however, these values are similar to those noted in our larger cohort. Our results also compare favourably with those seen in patients with BRAF V600E -positive metastatic melanoma (median progression-free survival 5·1 months and duration of survival 5·5 months). 24 Moreover, dabrafenib in this study showed better results than docetaxel and EGFR tyrosine-kinase inhibitors in unselected patients with EGFR and ALK wild-type tumours, where the proportion of patients achieving a response was 10% for each drug, progression-free survival was 2 months and 3 months, respectively, and overall survival was 7⋅0 months and 10⋅5 months, respectively. 17, 18, 25 The BRAF V600E mutant kinase is thought to be a promising therapeutic target for diff erent cancers, and inhibiting it is already a standard approach in malignant BRAF V600 -positive melanoma. 2, 26 Of note, though, the proportion of patients with a response in this study was lower than that seen with other targeted therapies in oncogene-driven NSCLC, including responses to EGFR tyrosine-kinase inhibitors in patients with EGFR activating mutations 27, 28 and responses to ALK inhibitors in patients with ALK rearrangements (usually responses are seen in >50% of patients). 29 The adverse events seen in our study were tolerable when compared with those reported for approved second-line and third-line therapies for NSCLC. 35 (42%) of the 84 patients treated with dabrafenib in this study had a serious adverse event, compared with 281 (45%) of 618 treated with docetaxel and 191 (37%) of 517 treated with erlotinib in previous studies. 25, 30 One patient in our study died from intracranial haemorrhage while being treated with dabrafenib and taking a factor Xa inhibitor. This death was judged by the investigator to be related to dabrafenib treatment. Some patients required dose interruptions or reductions, although patients generally received the intended daily dose. Adverse events were largely related to the skin (hyperkeratosis, skin papilloma, and dry skin). Dabrafenib, as with other BRAF inhibitors, was associated with development of cutaneous squamouscell carcinoma in ten (12%) patients or keratoacanthoma in seven (8%). The frequency of these adverse events is similar to that seen in patients receiving dabrafenib to treat melanoma. 13, 31, 32 Lesions generally appeared in the fi rst months of treatment and were eff ectively managed with simple resection without discontinuation of dabrafenib. No further prospective information was collected on these cancers because the study protocol mandated that they be removed surgically according to institutional practices. The adverse event profi le seems similar to that for treatment of melanoma except for higher frequencies of asthenia, decreased appetite, dry skin, and cough in this study. 13, 24, 33 Of note, we were unable to centrally confi rm BRAF mutational status at the time of this analysis. Although next-generation sequencing might improve genotyping of patients, we have not yet used this platform for central screening as no platform approved by the US Food and Drug Administration has yet been clinically validated. The need for more systematic profi ling of gene mutations to ensure that patients receive the most appropriate treatments in NSCLC is well accepted, but remains challenging for rare genomic changes (present in <1-2% of tumours). The ability to molecularly screen large numbers of patients with NSCLC was crucial in this study because of the low frequency of BRAF V600E mutations in this cancer (1·5%). 6, 8 Studies have shown that among BRAF-mutated melanomas, more than 80% harbour the BRAF V600E mutation, whereas only 50% of BRAF-mutant NSCLCs harbour this mutation. 7, 9, 10, 34 As BRAF screening is widely available for melanomas in most molecular platforms, local testing should be available in real time and should be reproducible in most oncology settings. The clinical characteristics of the patients reported in this study support the importance of screening all patients for oncogenic drivers rather than selecting them on the basis of clinicopathological characteristics (eg, non-smoking women) for multiplex genomic testing. BRAF mutations are seen in patients irrespective of smoking history, as opposed to EGFR mutations and ALK rearrangements, which are most frequent in never smokers (although BRAF mutations are seen almost exclusively in adenocarcinomas). Thus, molecular genetic identifi cation is crucial to optimise selection of patients with BRAF V600E -positive NSCLC for dabrafenib therapy and should include patients regardless of smoking history.
This study has some potential limitations. We included only patients with BRAF V600E mutations, which precluded the analysis of dabrafenib activity in wild-type NSCLC and in NSCLC harbouring other BRAF mutations, and we did not use systematic tumour biopsy upon progression to assess mechanisms of resistance to BRAF inhibition. Another potential limitation is the lower proportion of responses with BRAF inhibition than those seen with therapies targeted against EGFR mutations or ALK rearrangements. Upfront combined inhibition of MEK and mutant BRAF kinases may be a strategy to increase the number and duration of responses compared with BRAF inhibition alone, as has been seen in melanoma studies. 33, 35 In two other cohorts in this continuing study, combinations of dabrafenib and trametinib are being assessed: one cohort of patients receiving second-line to fourth-line treatment 36 and one cohort of patients receiving fi rst-line treatment.
Dabrafenib showed substantial antitumour activity leading to durable clinical responses in a substantial proportion of patients with BRAF V600E -positive NSCLC and had an acceptable safety profi le. Our results highlight the importance of screening for BRAF genetic alterations in patients with advanced NSCLC, particularly in patients with tumours negative for EGFR mutations and ALK rearrangements.
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